Good morning, everyone, and thank you for joining us this morning for VitalHub's 2023 second quarter conference call. Before we begin, I will read our cautionary note regarding forward-looking information. Certain information to be discussed during this call contains forward-looking statements within the meaning of applicable security laws, including, among others, statements concerning the company's 2023 objectives, the company's strategy to achieve those objectives, as well as statements with respect to management's beliefs, plans, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance, or expectations that are not historical facts. Such forward-looking statements reflects management's current beliefs and are based on information currently available to management and is subject to a number of significant risks and uncertainties that could cause actual results to differ materially from those anticipated. Our commentary today will include adjusted financial measures, which are non-GAAP measures. These should be considered as a supplement to, and not as a substitute for, GAAP financial measures. Reconciliations between the two can be found in our MD&A, which is available on sedar.com and our website. With that, I will hand over the call to our CFO, Mr. Brian Goffenberg, to go over our financial highlights for the quarter. Please go ahead, Brian. Good morning, everybody. Thank you for taking the time to join us this morning. We maintain our upward trajectory in the second quarter, steadily and consistently growing our customer portfolio by organic growth and mergers and acquisitions. During this quarter, we've seen a positive trend in both revenue and gross profits, fueled by our commitment to expanding healthcare product offerings and deeper integration into healthcare networks. This has led to a notable increase in stable annual recurring revenue of 31.4% for the first half of 2023. We remain very bullish on the diversified portfolio of product offerings we currently have at our disposal and will continue to target specific healthcare sectors to strategically scale and grow our business. With that in mind, I'll now proceed to present the financial highlights for this quarter. Total revenue for Q2 2023 totaled CAD 13.1 million, compared to CAD 9.5 million in Q2 2022, an increase of 38% year-over-year. Total revenue for the six months ended June 30th, 2023, was CAD 25.7 million, compared to CAD 18.9 million for the same period in 2022, an increase of 36%. Revenue from term licenses, maintenance, and support in Q2 2023 was CAD 10.2 million, compared to CAD 7.2 million in Q2 2022, an increase of 41%. Revenue from term license maintenance and support for the six months of 2023 was CAD 20.2 million, compared to CAD 13 million for the first six months of 2022, an increase of 56%. This increase reflects the impact of continued organic revenue growth in the company's suite of products, coupled with revenue derived from acquisitions completed during the previous quarters and year. Revenue from perpetual licenses in Q2 2023 was $255,058, compared to $149,253 in Q2 2022, an increase of 71%. Revenue from perpetual license for the first half of 2023 was $565,456, compared to $2.9 million the same period in 2022, a decrease of 81%. The decrease was primarily attributable to the unusual volume of high-margin perpetual license sales of $2.7 million in Q1 2022. Revenue from professional services and hardware in Q2 2023 totaled CAD 2.6 million, compared to CAD 2.1 million in Q2 2022, an increase of 25%. Revenue from professional services and hardware for the first half of 2023 was CAD 4.9 million, compared to CAD 3.1 million for the same period in 2022, an increase of 63%. The increase is primarily attributable to the deployment of the ongoing customer projects and additional service revenues from the new subsidiaries. Annual recurring revenue or ARR, of which we formerly referred to as annual contract value, totals CAD 41 million as of June 31, 2023, compared to CAD 31.2 million in June 30th, 2022, an increase of 31%. The continued increase in ARR growth is reflective of our strategy to grow the business both organically and through acquisitions. Gross margin on total revenue in Q2 2023 was 81%, compared to 83% for the same period last year, and gross margin on total revenue for the first six months of 2023 was 81%, compared to 84% in the same period in 2022. The decrease in both quarterly and year-to-date gross margins were due to the unusual volume of high-margin perpetual license revenue in Q1 2022 compared to this year. Operating expenses in Q2 2023 totaled $8.2 million, compared to $6.4 million in an operating expense in the first half of 2023 totaled $15.9 million, compared to $11.7 million in the same period last year, a 36% increase. The increase is due to sales and marketing expenses for conferences and the exhibitions and R&D expenses for acquisitions completed in 2023 and previous years as it takes time for synergies and cost savings to be recognized. Net income before income taxes in Q2 2023 was CAD 742,516, compared to a net loss of CAD 9,957 in the prior period. Net income before income taxes for the first half of 2023 was CAD 1.5 million, compared to CAD 1.6 million in the same period last year. Net income in Q2 2023 was CAD 621,000, compared to CAD 74,000 in Q2 2022, an increase of 733%. Net income for the first six months was $784,000, compared to $1.5 million in the same period 2022, a decrease of 48%. EBITDA in Q2 2023 was $1.98 million, compared to $1 million in Q2 2022, an increase of 93%. For the first six months of 2023, the EBITDA was $3.97 million, compared to $3.39 million for the same period in 2022, an increase of 17%. Adjusted EBITDA in Q2 2023 was $2.97 million, or 23% of revenue, compared to $1.87 million, or 20% of revenue in Q2 2022, an increase of 59%. For the first six months of 2023, Adjusted EBITDA was CAD 5.89 million, compared to CAD 4.92 million in the same period in 2022, contributing to an increase of 20%. The increase was primarily attributable to the higher recurring revenues of CAD 10.21 million in Q2 2023, as compared to CAD 7.23 million in Q2 2022. For the first six months of 2023, cash flow from operations before changes in working capital was CAD 4.1 million, compared to CAD 3.9 million for the same period last year. Cash on hand as at June 30th, 2023, was CAD 22.9 million, compared to CAD 17.5 million at the end of 2022. With that, I'd like to hand the call over to Dan for an update on the business. Thanks, Brian. I don't have that much to say today. I'll, I'll look for some questions from everyone that's out there just to add some clarity. Just a few comments to make. I think as you can see over the last quarters, Q2 is as steady as we go. We're, we-- You know, as I mentioned in our Q1 call, I think we've got ourselves into a stage where we are starting to be a little bit of a compounder here, and things are starting to work. I still think I got work to do. I think a little more size would, would help in terms of our organizations. As you can see, we're moving the needle on most of our key indicators on a quarterly basis, and we expect to continue to do that. Our ARR is growing, above our expense level at this stage in the game. We still think we got room on the expense side to do some things. It's steady as we go. We're still seeing demand for our products. We're still... I don't know how many quarters it's been now, but, you know, we're doing between CAD 800 and CAD 1.5 million in the last two quarters of being closer to the higher end of that set. It's really split amongst our products, in terms of number of deals and deals that are there. Of note on our product set, our TREAT product set in the Canadian marketplace is seeing some really good momentum in the last little while. We're excited of what we're doing in the Canadian opportunity. It is turning into a Canadian standard for larger-based initiatives, where community and mental health agencies are combining or looking to get to the next level. We've consistently been winning some tenders in that space. The Transform product in the U.K. continues to steadily produce. The Oriel product, the education platform of the Hicom acquisition, continues to add users on, on a quarterly basis. We're also starting to see impact from the CDS company in Australia as well. We, we are seeing a little bit of a slower turn on our Intouch product sets. It's still producing, but, you know, that quarter that we had in 2022 is long gone at this stage in the game, but we're still seeing impact from there. We're making great progress on our cost side. We continue to ramp up our Sri Lankan Innovation Lab. Really proud of what that group's done. It, you know, it's not just QA and development anymore. We got IT operations support. They're doing implementations, consulting, new versions of product, updates and so forth. They're all starting to go through there, so we're there. We still think there's room to expand on across geographies. We're starting to see some work in that, in that realm, especially in the Canadian marketplace, with some of the Intouch product sets. We're, we're still seeing growth on our products, you know, across the board, so we're happy with the way that's going. You know, traditionally, Q3 is a slower quarter, mainly because it's hard to get services over the finish line. I think we're doing okay so far, but it is pretty hard to get government agencies to do the work in the, in the quarter. We always worry about this quarter, but we're continuing to progress it. On the acquisition side, we're still seeing deal flow. We've been cautious in that regard. There were a couple scenarios that we didn't do because we didn't like the way they turned out, but we do have stuff in the works, and we continue to work those areas. We're still sitting on a significant amount of cash. I think we saw our, our balance go close to CAD 23 million in the quarter. Note the accounts receivable amount in our balance sheet. We expect that number to continue to go up as we continue to progress through, through our deals and through our business model. We're happy with, with what we're doing. I think if you take cash and look at our valuation, I think we're at, like, a CAD 90 million enterprise value-based company right now. And we expect to continue to have cash and AR and continue to grow on those lines. We're, we're gonna just keep executing the plan and keep doing what we're, what we're doing. We're open for any questions. Perfect. Thanks, Dan. Should you have any question, please use the Zoom raise hand function on the bottom of your screen, and we will make sure to open your line. First question is from Richard Baldry of Roth Capital. Go ahead, Richard. Thank you. I'm mobile, so hopefully I'm not too garbled. Could you talk about the spike in deferred revenue in the quarter? Obviously, that's a disproportionate cash generator when it can run hard. It was up almost over 50% sequentially. Maybe let us know how that happened, what's sustainable about that, or one-time oriented? It's a combination, and Brian can add some light on this as well. It's a combination of, you know, annually, we did some more acquisitions, so it's inherently that's gonna grow. We're also a pretty cyclical business in terms of our recurring time frames, right? We do a lot of stuff that gets renewed in Q1, which would increase the at the end of Q1, which would increase the deferred balance in Q2 as we go through it, and then we've added some deals into, into that scenario. Deferred is often a, a question of the timing of when the contracts were, were signed. Brian? Yeah, I think to, to add to, to that comment, really, there was a fair amount of billing that went out towards the end of the quarter, of which the revenue will only be recognized in the following quarters. It's just really timing. Okay, got it. You set another, you know, narrow new high for Adjusted EBITDA, but at the same time, you know, we're seeing you're able to invest pretty strongly in sales and marketing and R&D on a sequential uptick basis. Can you talk about, you know, are those sequential upticks or opportunistic hiring or in response to some of the demand you're seeing? Do you think that the new levels we're seeing are sort of sustainable here forward? We have, we have ramped up some, some new hires in terms in Australia and the Canadian marketplace to try to get some cross-selling and some synergistic work out of some of our product set. We have done a bit of that on the sales and marketing and, and beefed up that. There are some products that we think have better potential from a sales perspective. You know, we are putting a little bit more development into those, into those as well. Last for me would be, you know, revenues were up sequentially, and, and the COGS line actually fell very narrowly, but, you know, let's call it flat. You know, are you seeing incremental areas of synergies there, or, you know, maybe was 1Q a little ahead of trend, and so it was easier to go sideways even as the revenues were climbing? Thanks. COGS are usually attributed to two things that sort of fluctuate that line for us. One is we deliver more professional services, we got a higher cost of goods. Two, the hardware component on, on those deals, on some of our deals, we have one product that is hardware-based, so we get a little bit of a hardware spike. You'll see the COGS increasing on there. You know, we look at our costs synergistic. We're all like, we're always trying to figure out ways to be a little bit more innovative, to move things into our Colombo Innovation Group, you know, where, like, things like IT resources, help desk, 24/7 support, things that we can do to move sequentially down, you know, move things over there. We're always thinking of those things, Richard, and it, it's constant, and it will always be constant, that we're just trying to think of out of the box in that area. Great. Congrats on a good quarter, especially on the cash generation, and especially in a tough environment. Thanks. Thanks, Richard. The next question is from Gavin Fairweather of Cormark. Gavin, your line is open now. Oh, hey, good morning. Can you hear me? Yeah. Yes, we can. Okay, great. Daniel, you referenced the ARR range of kinda CAD 800,000-CAD 1.5 million. Nice to see you coming in kind of at the higher end of the range. You know, I typically think tends to be a bit of a seasonally slower quarter. Is that still kind of the right range for you? Do you think that as you get into the busier sales period, you could actually poke above that, that range? How do you think about the kind of sales potential of the business on a quarterly basis? You know, there, you could see spikes and valleys in, in this thing. You never know. Like, it, it's government healthcare, right? Funding envelopes open up. Sometimes they're not opened up, right? You, you just don't know where, where that's gonna go, right? You know, if we hit between CAD 800,000 and CAD 1.5 million and don't miss it, and we keep our... Yeah, maybe we'll be on the low end, one side of the quarter, but we're still generating cash, right? If that's up and it's still coming to the bottom line of next quarter. This is the long game for us. Based on our current product set, I think the CAD 800,000 to CAD 1.5 million is probably the number which I feel comfortable with. You know, more acquisitions will lead to different product sets and, you know, there, there's some growth product sets that are out there. I think we can increase it, but, you know, that's where I feel comfortable at this stage in the game still. Got it. Then maybe on the Australian market, you mentioned it as, as seeing some increasing traction. You know, I know you added some sales resources there on the patient flow side. You're also planning on taking kind of TREAT into that market. I know it's still kind of early days from a revenue perspective, but maybe you can just discuss kind of the demand environment and, and the reception to, to some of your increasing sales investments in the region. Well, we have with CDS, we got the ability to execute, you know, by adding support people and salespeople and making sure that they're gonna get proper supervision and management. So we, you know, we got the structure in there to, to execute. It'll take some time for that to happen. We do got a base of about a dozen Intouch customers. I think we got a large MCAP customer already in Australia, and you got your CDS customers. We did ramp up a new sales team that, you know, has gone through and is being onboarded and is starting to progress in, in those areas. We've also introduced the TREAT product into the CDS group, who's got the ability and the domain experience to sell it, and the, you know, and we're starting to see tenders and things come through there. We're starting to understand what we need to do to tweak the product a little bit to the marketplace. The product is being well received based on what we've shown people so far, and we're starting to feel that product can expand into other markets besides Australia as well, based on the results that we're getting in Canada. We're, we're beating some pretty high-profile names with that product set, and there's been a ton of R&D that's gone into it over the last three, four years. It's a, it's a pretty big team, and we're, we're happy with the way that product's progressed. We're, we're continuing to push the envelope on that product. These are slow sales processes. They're larger transactions. We'll just keep pushing the envelope on it. What about TREAT in the U.K.? Yeah, we're starting to see some, some opportunities for that. Ideally, Enter TREAT ideally, I'd like to enter that with an acquisition in the U.K., which would be a great thing for us to do. We are, we are doing a little bit there, but it, it takes a, you know, it takes a team to support that, that really understands that domain and, and that grouping. It's a lot more complex of an implementation and sales process, we don't really want to make the investment in a team. Ideally, we'd like to do that through an acquisition. Makes sense. If we were speaking, I guess, first half of 2022, you know, you would have said that your goal was to grow the business to kind of $50 million, and obviously, you've been there for kind of a couple quarters. Do you have any other kind of fresh targets in mind and, and thoughts around kind of timelines around those? Like, what's the dot on the wall internally now that you've achieved that $50? Listen, it would, it would be nice to get to the CAD 75 million-CAD 80 million range, with the same, with, with the same metrics that we have, producing right now. Well, you know, going at it organically will be a, a little bit of a slow growth, every quarter we get some cash, we'll do acquisitions. We've still got the acquisition line. Ideally, a larger acquisition that is very, synergistic with, or would be the ideal way that we'd like to go here, at the same time, that's a pretty big decision to make, and we'd have to be really careful in, in how we make that. We're continuously progressing and looking for those avenues, and we'll see what happens. Okay. I'll Rick you. Congrats on nice combo of organic growth and, and margin and cash flow here. Thanks. Thanks, Gavin. The next question is from Christian Sgro of Eight Capital. Go ahead, Christian. Hey, good morning, Dan and Brian, and congrats on some good organic growth in the quarter and good results overall. You know, following on Gavin's question, Q2 isn't normally the strong seasonal one, but hit that high end of the sequential add. You know, I guess absent a flurry of new customer announcements in the U.K. or otherwise, would you say that a lot of the ARR add was expansion? Then I might ask separately about Canada, but was some of the deployments in Canada, was that a big part of the growth this quarter? Combination of everything. We keep adding users on the Oriel platform. We're not announcing every transaction at this stage in, in the game, you know, to do that. Some of our customers don't want them announced, and just because of the government sector of where it's at, and we're just not announcing every single little deal anymore. We're just, we're, we're letting, you know, things go through there. It's been a combination of everything, and there's been some add-ons to the Oriel product. There's been some rollouts on the TREAT product that have brought that into, bought those deals and allowed us to recognize licensed revenue in there. Transform continues to add stuff on a consistent basis. We've, we've seen it across all the areas of our business. CDS traditionally always adds CAD 100,000-150,000 per quarter, and they're all small deals, but they consistently add them. We got growth coming from many different areas these days, Christian. That's really what's going on. That's great. I'll still ask a separate question on Canada, but you had mentioned- Yeah. There was TREAT momentum. Yeah. Would you say? Yeah, we're seeing consolidation, and we're seeing decommissioning of older legacy systems that were being run by government bodies, that they're looking for new, looking for new vendors, and we're winning those RFPs. We expect to see a flurry of TREAT deals over the next few quarters. Great. That's all in the pipeline. It was, it was a forward-looking comment- Yeah which is good. I'll ask, maybe just one more poke at the M&A, your appetite there and, and what you're looking for. Would you stick to the same plan that you've had for, for three-plus years, high margin, recurring, something adjacent, or is there anything else you're seeing that could be attractive to you? Any call you want to give on the geography or the personality? Yeah, I think if it's something, we would enter a new type of, maybe not new geography, like, new geographies other than the United States. We're still not ready to go there, new geographies, for sure. We're, we're looking for the similar type of product sets. We know the gaps that we're trying to fill in, in those gaps, and we're, we're targeting those, those organizations that we're either working with or competing against in the field. We're, we're consistently looking. You know, we'll do the, you know, the million-dollar recurring businesses-... Those things are still out there, and we expect to execute on a few more of those. We still got some larger ones that are in the works as well. We, we continue just to do what we're doing. I think the last two, three quarters, we being a little bit careful to make sure that we got ourselves into a cash generation engine, which I think we have. We just wanted to make sure that we can self-fund these things, and, if we do dip into our debt facility, it really needs to make sense from a synergistic perspective. We would want to have a profitable organization out of the get-go for that or, and so forth, so that we know we could carry that debt. Where the smaller ones, they're not profitable yet, we'll make them profitable very quickly. That's easily done. The bigger ones, a little bit more challenging. We just wanna be careful as we move through there, and, you know, we're looking at all over, as we always have been. You know what? I'll sneak in a fourth for Brian, but it's, it's quick and mechanical. On the income statement, Brian, for the operating lines, was there some reallocation from Q1 to Q2, some of the G&A going to R&D? You know, not, not a huge impact to the overall profile, but to help us with modeling. It looks like there were just some, some shifts there. Yeah, there, there was a, there was a little bit. We've got, we've put a new system in place, which allows us to better allocate some of the, the people side, so there was a little bit of a, a reallocation. Perfect. That's all from me. Thanks so much for taking my questions. Thanks, Christian. Next question is from Doug Taylor of Canaccord. Doug, your line is open. Hi, good morning. This is Neil Bakshi on behalf of Doug. He was on another call, unfortunately. Congratulations first on the quarter. Good organic growth and free cash flow, so there's that code. The first question I have, you'd mentioned the Intouch product set was a little bit of a down quarter. Just wondering, in terms of, you know, resource allocation or, you know, efforts to, you know, see growth return back to its previous levels, look at in terms of Intouch as a standalone. It's like, there's two things with the Intouch. Number one is where we've tried to evolve, move that into a recurring revenue model from a professional model with some success, but not, not totally, right? There's still a little bit going. It's still coming through, but more to the recurring side versus the professional side. 'Cause the professional side just sort of slung that number a little bit. But it, because there's a hardware component that gets sold with that, the perpetual seems to be the way that those customers would like to buy that, because we're not gonna, we're not ready to do recurring models on the hardware just because we don't make much margin on it, which doesn't make sense. We wanna get paid for that stuff upfront as we support it. Of course, the license needs to roll into it. They got a pretty big penetrated base in the U.K. We've, we've had some success in Australia with it, and we're, we're trying to move it into the Canadian markets and so forth, but there's still enough left in, in the U.K. to sell. I still expect that we're gonna sell that product, and we'll continue to sell it, and it's still. That business unit still produces really good margin for us, so we expect to, we expect for it to continue. You know, in the U.K., we've integrated our groups together pretty nicely, except Hicom at this stage. We can move resources around from, you know, the Intouch group can start helping with Transform and, and the BI groups and so forth, et cetera. We have the ability to move resources around, which is part of a good, another good concept of our business model. It's not that, you know, if, if, if the timing is not right for it, we see an uptick in Transform, which we are and expect to continue. Moving resources from the projects team and the implementations teams can be done, so that's part of our plan as well in the U.K.. Great, thank you. Just a question with respect to S12. You'd mentioned, I guess, in a previous update, that we could see a bit of an uptick later this year as new modules are added, but just wondering how progress is going with that product? Yeah, we did a little. In Q2, we didn't see much impact, but those, those two product sets are... One is totally completed and in the market, and we're starting to see stuff for Q3, and the other one is coming around as well. We do expect a little bit in Q3 and in Q4, we do expect to see some more impact into next year as well. Okay, great. Thank you. Thanks, Neil. Next question is from Daniel Rosenberg of Paradigm. Daniel, your line is open. Hi, good morning, guys. Hi, my first question was just around the use of the resources you have. You know, you've reached a point where, you know, momentum is, is strong on all fronts, the cash pile is growing. Outside of M&A, has it changed your think, Has it changed your thinking on what to invest in, whether it be, you know, new product internally, targeting new verticals or adjacent verticals? Has your thinking changed at all about what you can allocate capital to? Yeah, we're, we're, we're still pretty careful on capital allocation. We, we, we have generated some capital into the Canadian and Australian marketplace to expand sales and marketing. We, we've done that a while. There's other product sets, which we think are newer sets that need some more development group, like the ADI product we acquired last year, the MyPathway product and the Synopsis product or Intouch product, which we think need some more R&D done on them. We, we, you know, we invested in, in increasing the R&D base function. We, we need to consistently develop our products to maintain their leadership positions in some of those markets. The transforming product still consistently gets development. Yeah, we, we do ramp up our costs in some areas to go do that, but we try to move that into our Colombo group as much as we can to do that. From a sales and marketing perspective, we're not gonna be this organization that's gonna go into a new geography unless it's with a partner or with an acquisition very easily. It's an expensive process, and it's very difficult to do, but acquisitions are the way to enter those markets. We, we did make the investment in Australia, so that's one of the areas, and Canada, of course, we got a base already, so that's another area. Healthcare is very tied to their geography, and, and breaking into that culture of the-- of how that healthcare system works really takes people that have been in that space for a while to really understand it. We want those people. Those, those people are really, you know, part of what our assets are, and we'd like to acquire those assets and expand those assets with expanding into products versus just risking it by going in there. Yeah. Then on the, the success you've had in kind of community health, I mean, healthcare is just a massive market. Are there any areas that you would ever consider expanding into? Community health is just... You know, obviously there's plenty of runway for you, you know, it feels like you're kind of at a different point in your story. Yeah, there's a lot, there's a lot of community health vendors out there, right? Like, you know, all those areas need to be digitized, but they're all, they are moving to, you know. This world has changed into, like, I don't have anything, so I need something better world. We're starting to, we're saying we need something better, and we think we have that better product with the TREAT solution. We're progressing into those worlds, and those other organizations that don't have the better solutions become acquisition targets, right? That's really, in that particular area, it's to keep expanding the TREAT product and keep growing it and keep buying inferior products that we can upsell them to the TREAT product. That's what our business philosophy is there. Okay, I appreciate that, and I'll echo the comments. Congrats on continued success. Thanks, Daniel. Thanks, Daniel. Next question is from Gabriel Leung of Beacon Securities. Gabriel, line is open. Morning. Thanks, Dan, just got a couple questions on the M&A side of things. Just curious, have you found the M&A environment a bit less competitive now, just given the current cost of capital? Concurrently, you know, have you seen seller expectations become, I guess, more reasonable, vis-à-vis past couple of years? Actually one more thing as well on the M&A. You mentioned during your preamble that, I guess you were close to the finish line on a couple of opportunities, but, I guess at the end, it didn't tick the boxes. I'm just curious to hear what those boxes might have been. Yeah, let me answer that. Yeah, I think we sort of predicted this when the markets would go down, right? The sellers at first don't. You know, they're still sticker. The prices were still high. I think a lot of people took their things off of the market. We are starting to see some more deal flow, but, you know, sort of these companies that have tried to get out of the box and sort of have a little bit got out of the box, and they've raised capital, but now that capital is dead. We're seeing a bunch of scenarios where they got, like, three or four implementations. You know, they're bringing in CAD 300,000-CAD 400,000 worth of recurring. It's a really neat product, but it's not totally done yet. They got customers that like it, but they really need investment more than they need acquisition. We're. Some of those are a little bit more on the larger side, too. We're, we're careful of those, right? Where the product is there. We think it's there, but then we get through the due diligence, it's not actually fully there yet. It's still, it needs this work, it needs that work to be competitive. We, we, we'll take those on if it has enough scale because we think we can add to things if we can do it, but if it doesn't have enough scale, we get a little bit worried about it, and those are a couple of the scenarios that you have. The other scenario, just the accounting wasn't what they thought it was, right? You know, some people just don't, some accounts just don't understand recurring revenue, the way that it should be done. That's what you see in some of these smaller acquisitions and smaller target sets. In general, I think we are seeing a little bit more of an uptick on the M&A side as capital. You know, people thought it dried up, but they would wait, and now they waited, and it's still dried up. I think there are a little bit more scenarios that are cooking, or maybe it's just opportunistic, but we do see more deal flow floating around in the summer of this year than we did towards the end of last year, type of thing. We're progressing. This opportunity has given us a little bit of time to digest these acquisitions. We needed that. We've revamped a bunch of processes in terms of our data analytics and our operations and so forth. We're positioned really well to absorb acquisitions right now, and we're actively looking. Gotcha. Thanks for that. Then just shifting over to the, I guess, the growth and demand side of things. I'm curious if you, you know, sort of heard anything, from your customers, prospective customers, that might give you worry, that, might, might give you worry about your ability to hit sort of that, that booking, quarterly bookings range you've talked about. Sort of concurrently, is there anything internally within VitalHub Corp. you feel you can sort of tweak to, to help the business consistently hit out of that range or the upper end of that range, I guess? Yeah. You know, you always got, you always got your pricing your, your price increases and things like that, which we do, probably a lot more conservative than a lot of organizations. There's probably still room for tweaking on that perspective. We sell a lot to these customers, so we don't like to play that game, totally in a you know, in a, in, in a bad fashion, so we're, we're careful. From a perspective, the growth needs to come by expanding to other geographies or adding add-ons or more acquisitions. We still think there's enough of a TAM for our products, that we still got, you know, a couple years of runway at these... at, you know, adding to these rates, right? Between 800 and the 1.5 level. We'll make more acquisitions for some growth products, which will allow that to grow. We, we expect to be able to continue to, to think of ways and be innovative to go do that. You know, it's not the end of the world if we don't do it a few quarters here and there, as long as we got our expense level. We look at this as a steady as you go. Like, you know, some, you know, some quarters we'll add CAD 3 million-CAD 4 million of Adjusted EBITDA, and maybe we'll have a quarter where we do, 'cause we didn't sell a lot, and we do CAD 1.5 million-CAD 2 million. You know, three months later, we'll be back to doing the CAD 3 million or CAD 4 million. You know, we look at this as a, as a bigger picture. As long as we're continuously, you know, building up and adding cash on a consistent basis and got the model to do it, we're happy as an organization, and we're not gonna lose sleep, or we're not gonna go take risk of investing in sales and marketing to go get that other world, 'cause that's not what this space is all about. Gotcha. No, thanks for all the feedback, and congrats on the progress. Yeah. Thanks, Gabe. There are no further questions. I would like to now thank everyone for joining us this morning and hand over the call back to Dan for his closing remarks. Yeah. Thanks, everyone. No, it, it's just the same theme as anything. I think we got. I keep saying we, we think of three things here every day. We're trying to do accretive acquisitions for synergistic products, and trying to do those acquisitions at the right price, even if it's not the right price, but it'll be accretive down the road, that's okay with us as well, to do that. We, we do got the ability to execute by using our Colombo Innovation Lab as effectively as possible, and we, we try to bring as much there from a cost reduction perspective. We're always looking for organic growth with high margins. You know, we think of those things every day, and, and, and we're always, we got some pretty good analytics going on in the company, and we just keep tweaking our business models accordingly. We're gonna have some. You know, things are good right now. We might have a bad quarter, but it still won't be bad. It'll still be generating cash. We, we just keep going and that's what the business model is here, and we're looking for investors that like the idea and like the steady growth and just like the economics of it. It's, you know, relative to what other things are out there, like, we're. I don't know. I don't know how many companies are out there with, like, $41 million of recurring, you know, $3 million of Adjusted EBITDA and trading at a $90 million enterprise value market cap when you take the cash off. That's where we're at right now. I guess it's just a sign of times of the market, but, you know, our job is just to make the investors aware of what this is all about, and hopefully, we do that. If you wanna know more, feel free to give us a shout. We're always open to talking to any investor, from an institution to an individual, and trying to explain the business model in more depth to them. If anybody has ideas, feel free to reach out to us. Appreciate it. Thanks, Dan. This concludes today's call. Thanks, everyone. Okay. Bye-bye. Thank you. Bye. Bye-bye.